Oscar Clinical Guidelines: Pharmacy
Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Oscar may delegate utilization management decisions of certain services to third-party delegates who may develop and adopt their own clinical criteria. The clinical guidelines are applicable to all commercial policies. Coverage of services is subject to the terms, conditions, limitations of a member’s policy and applicable state and federal law. Please reference the member’s policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits) or to confirm coverage contact 855-672-2755 for Oscar Plans and 855-672-2789 for Cigna+Oscar Plans. Looking for medical guidelines?Click hereLooking for our Archived guidelines? Click here.
Upcoming Policy Changes
- 2025 Q2 (June) P&T Summary of Changes
- 2025 Q3 (July) P&T Summary of Changes
- 2025 Q3 (August) P&T Summary of Changes
- 2025 Q3 (September) P&T Summary of Changes
- Effective 11/1/2025
- Armodafinil (Nuvigil) (PG036, Ver. 8)
- Cibinqo (abrocitinib) (PG111, Ver. 4)
- Dexlansoprazole (dexilant) (PG047, Ver. 8)
- Fesoterodine (Toviaz) (PG102, Ver. 6)
- Filsuvez (birch triterpenes) (PG211, Ver. 2)
- Furoscix (furosemide) 8mg/1mL Solution for injection [On-Body Infusor] (PG132, Ver. 5)
- Icosapent ethyl (Vascepa) (PG125, Ver. 4)
- Injectable Iron Supplements (PG196, Ver. 4)
- Mitoxantrone (Novantrone) (PG126, Ver. 4)
- Orilissa (elagolix) (PG261, Ver. 1)
- Pancreatic Digestive Enzymes - pancrelipase (Brand Names: Creon; Pancreaze; Pertzye; Viokace; Zenpep) (PG027, Ver. 7)
- Quantity Limit Exception Criteria (PG200, Ver. 3)
- Spevigo (spesolimab-sbzo) (CG071, Ver. 5)
- Sunosi (solriamfetol) (PG097, Ver. 6)
- Vyvanse (lisdexamfetamine) (PG098, Ver. 6)
- Wakix (pitolisant hydrochloride) (PG247, Ver. 2)
- Wegovy (semaglutide) for Cardiovascular Risk Reduction or Metabolic Dysfunction-Associated Steatohepatitis (MASH) (PG194, Ver. 4)
- Zortress (everolimus) (PG033, Ver. 7)
- Effective 12/1/2025
- 2025 Q3 (July) P&T Summary of Changes
- Amvuttra (vutrisiran) (PG264, Ver. 1)
- Antidiabetic Agents - Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (PG152, Ver. 6)
- Aptiom (eslicarbazepine acetate) (PG174, Ver. 3)
- Azelaic acid 15% gel (PG059, Ver. 7)
- Benlysta (belimumab) (PG014, Ver. 8)
- Briviact (brivaracetam) Tablet, Solution (PG172, Ver. 3)
- Continuous Glucose Monitors (CGMs) (PG121, Ver. 7)
- Dipentum (olsalazine sodium) (PG244, Ver. 2)
- Direct Acting Antiviral Agents for Hepatitis C (PG045, Ver. 7)
- Doxylamine/Pyridoxine (Bonjesta, Diclegis) (PG096, Ver. 6)
- Fycompa (perampanel) (PG176, Ver. 3)
- lamotrigine extended release (Lamictal XR) (PG055, Ver7)
- Lamotrigine Orally Disintegrating Tablet (PG083, Ver. 7)
- Memantine (Namenda) (PG213, Ver. 2)
- Methotrexate Injectable Solution (PG249, Ver. 3)
- Non-Formulary Mental Health Products Criteria (PG265, Ver. 1)
- Prescription Drugs for Serious Mental Illnesses-REG (PG171, Ver. 3)
- Rebyota (fecal microbiota, live - jslm) (PG240, Ver. 2)
- Restasis (cyclosporine 0.05% ophthalmic emulsion) (PG025, Ver. 8)
- Rivastigmine (Exelon) (PG212, Ver. 2)
- Tysabri (natalizumab) (PG195, Ver. 4)
- Varubi (rolapitant) (PG178, Ver. 3)
- Verkazia (cyclosporine ophthalmic emulsion) 0.1% (PG236, Ver. 2)
- Vowst (fecal microbiota spores, live-brpk) (PG241, Ver. 2)
Pharmacy Guidelines
- armodafinil (Nuvigil) (PG036, Ver. 7)
- Aripiprazole oral disintegrating tablet, solution (PG173, Ver. 3)
- Adbry (tralokinumab-ldrm) (PG110, Ver. 7)
- Adakveo (crizanlizumab) (PG193, Ver. 2)
- Adefovir Dipivoxil (Hepsera) (PG081)
- Albendazole (Albenza) (PG101)
- Allergen Sublingual Immunotherapy (SLIT) (PG093, Ver. 6)
- Alvesco (ciclesonide)(PG105)
- Antidiabetic Agents - Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (PG152, Ver. 5)
- Antidiabetic Agents - Soliqua, Xultophy (PG153)
- Antidiabetic Agent - SymlinPen (pramlintide acetate) (PG156)
- Anti-migraine Agents/ Calcitonin Gene-Related Peptide (CGRP) Antagonists and Serotonin Receptor 5-HT1F Agonists (PG008)
- Approved and Accepted Off-label Medical Necessity Criteria for Products, Drugs and Biologicals (PG136, Ver. 3)
- Aptiom (eslicarbazepine acetate) (PG174)
- Asenapine (Saphris) (PG058)
- Authorization Duration Exception-REG (PG269, Ver. 1)
- Auvelity (Dextromethorphan and Bupropion) (PG128)
- Avonex (interferon beta-1a) (PG218, Ver. 2)
- Azelaic acid 15% gel (PG059)
- Azstarys (serdexmethylphenidate and dexmethylphenidate) (PG130, Ver. 3)
- Bafiertam (monomethyl fumarate) (PG219, Ver. 2)
- Belsomra (suvorexant) (PG064)
- Benlysta (belimumab) (PG014)
- Benzodiazepines for Acute Repetitive Seizures or Seizure Clusters (PG254, Ver. 4)
- Betaseron (interferon beta-1b) (PG220, Ver. 2)
- Beqvez (fidanacogene elaparvovec) (CG118)
- Beyfortus (nirsevimab-alip) and Enflonsia (clesrovimab-cfor) (PG180, Ver. 3)
- Botulinum Toxin (CG033, Ver. 15)
- Brand Medically Necessary Drugs (PG186)
- Brimonidine/Timolol (Combigan) (PG103, Ver. 6)
- Briumvi (ublituximab) (PG134, Ver. 5)
- Briviact (brivaracetam) Tablet, Solution (PG172)
- Budesonide 3mg Capsule (Entocort EC) (PG082)
- Caplyta (lumateperone) (PG175, Ver. 3)
- Casgevy (exagamglogene autotemcel) (CG113, Ver. 3)
- CeQur Simplicity Insulin Delivery System (PG192, Ver. 3)
- Cibinqo (abrocitinib) (PG111)
- Cobenfy (xanomeline and trospium) (PG253)
- Collagenase Ointment (Santyl) (PG141, Ver. 3)
- Combination products for treamtent of helicobacter pylori (PG199, Ver. 2)
- Continuous Glucose Monitors (CGMs) Prescription Products (PG121, Ver. 6)
- Cromolyn Sodium Oral Concentrate (PG087)
- Dalfampridine (Ampyra) (PG217, Ver. 2)
- Dapsone 7.5% topical Gel (Aczone) (PG214, Ver. 2)
- Daybue (trofinetide) (PG148)
- Difluprednate (Durezol) Ophthalmic Drops (PG079)
- Dimethyl Fumarate (Tecfidera) (PG222, Ver. 2)
- Dipentum (olsalazine sodium) (PG244)
- Direct Acting Antiviral Agents for Hepatitis C (PG045)
- Disposable Insulin Pump Devices (PG127, Ver. 4)
- Doxylamine/Pyridoxine (Bonjesta, Diclegis) (PG096)
- Duaklir (aclidinium/formoterol) (PG107)
- Dupixent (dupilumab) (PG026, Ver. 14)
- Elevidys (delandistrogene moxeparvovec-rokl) (PG160)
- Emverm (mebendazole) (PG001)
- Entecavir Tablets (PG085)
- Eohilia (budesonide) (PG216, Ver. 2)
- Eucrisa (crisaborole) (PG023, Ver. 7)
- Exemestane (PG084)
- Extavia (interferon beta-1b) (PG223, Ver. 2)
- Ezetimibe (Zetia) (PG073, Ver. 7)
- Febuxostat (Uloric) (PG066)
- Fesoterodine (Toviaz) (PG102)
- Fetzima (levomilnacipran) (PG063)
- Filsuvez (birch triterpenes) (PG211)
- Fingolimod (Gilenya, Tascenso ODT) (PG224, Ver. 2)
- Fleqsuvy (baclofen oral suspension) (PG112)
- Furoscix (furosemide) 8mg/1mL Solution for injection [On-Body Infusor] (PG132, Ver. 4)
- Fycompa (perampanel) (PG176)
- Glatiramer Acetate (Copaxone, Glatopa) (PG221, Ver. 3)
- Growth Hormones (PG049)
- Hemangeol (propranolol hydrochloride oral solution) (PG135, Ver. 3)
- Hormonal Therapy for Gender Dysphoria Zero Copay Exception (PG184)
- Ilaris (canakinumab) (PG185)
- Imcivree (setmelanotide) (PG088)
- Immune Globulin Weight-Based Dosing Criteria (PG256, Ver. 1)
- Infertility Injectable Agents (PG119)
- Injectable Iron Supplements (PG196)
- Insulin Delivery Systems and Continuous Glucose Monitoring (CG029, Ver. 15)
- Ivermectin 1% Topical Cream (PG239)
- Izervay (avancincaptad pegol) (PG168, Ver. 3)
- Journavx (suzetrigine) Quantity Limit Exceptions Criteria (PG260, Ver. 1)
- Kesimpta (ofatumumab) (PG225, Ver. 3)
- Kisunla (donanemab-azbt) (PG238)
- Lacosamide (Vimpat) (PG056)
- Lamotrigine ER (Lamictal XR) (PG055)
- Lamotrigine Orally Disintegrating Tablet (PG083)
- Lamzede (velmanase alfa-tycv) (PG146)
- Lanthanum Carbonate Chewable tablet (Fosrenol) (PG177)
- Lantidra (donislecel-jujn) (PG167)
- Lazcluze (lazertinib) (PG251)
- Lemtrada (Alemtuzumab) (PG226, Ver. 2)
- Lenmeldy (atidarsagene autotemcel) (CG117, Ver. 2)
- Leqembi (lecanemab-irmb) (PG138)
- Lidocaine Transdermal Patch (PG124)
- Lidoderm (lidocaine) 5% Transdermal Patch (PG124, Ver. 4)
- Livtencity (maribavir) (PG113, Ver. 4)
- Lokelma (sodium zirconium cyclosilicate) (PG143, Ver. 3)
- Lumryz (sodium oxybate) (PG246, Ver. 2)
- Lurasidone (Latuda) (PG057)
- Luxturna (voretigene neparvovec-rzyl) (CG060)
- Lyfgenia (lovotibeglogene autotemcel) (CG114)
- Mavenclad (cladribine) (PG227, Ver. 2)
- Mayzent (siponimod) (PG228, Ver. 2)
- Medications for Cosmetic Purposes (PG080)
- Medical Necessity Prior Authorization Criteria (PG076)
- Memantine (Namenda) (PG213)
- Mesalamine DR 800 (Asacol HD) (PG024, Ver. 7)
- Methotrexate Injectable Solution (PG249)
- Miebo (perfluorohexyloctane) (PG166)
- mitoxantrone (Novantrone) (PG126)
- Modafinil (Provigil) (PG035, Ver. 7)
- Myrbetriq (mirabegron) (PG181)
- Neffy (epinephrine nasal spray) (PG243, Ver. 2)
- Nevanac (nepafenac) Ophthalmic Suspension (PG078)
- NexoBrid (anacaulase-bcdb) (CG112)
- Niktimvo (axatilimab) (PG252, Ver. 2)
- Non-Formulary Products Criteria (PG069)
- Ocrelizumab (Ocrevus, Ocrevus Zunovo) (PG235, Ver. 4)
- Ohtuvayre (ensifentrine) (PG237)
- Omega-3-acid ethyl esters (Lovaza) (PG005, Ver. 7)
- Omisirge (omidubicel-onlv) (PG149)
- Opioids (PG018)
- Orgovyx (relugolix) (PG089)
- Orgovyx (relugolix) (PG089-REG)
- Orladeyo (berotralstat) (PG090)
- Osphena (ospemifene) (PG169)
- Oxiconazole (Oxistat 1%) (PG100, Ver. 6)
- Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] (PG245)
- Pancreatic Digestive Enzymes (pancrelipase) (PG027)
- Pedmark (sodium thiosulfate) (PG133)
- Prescription Digital Therapeutics (PG142)
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (PG068)
- Phenoxybenzamine (PG054)
- Phenoxybenzamine (PG054-REG)
- Plegridy (peginterferon beta-1a) (PG229, Ver. 2)
- Ponvory (ponesimod) (PG230, Ver. 2)
- Potassium Chloride Oral Solution (PG086)
- Prenatal Vitamins Zero Copay Exception-REG (PG258, Ver. 1)
- Prescription Drugs for Serious Mental Illnesses-REG (PG171)
- Preventive Services Statins Zero Copay Exception (PG159)
- Proton Pump Inhibitors - Esomeprazole and Rabeprazole (PG047)
- Roctavian (valoctocogene roxaparvovec-rvox) (PG163)
- Qalsody (tofersen) (PG151)
- Quantity Limit Exception Criteria (PG200, Ver. 3)
- Rasagiline 1mg (PG065)
- Rebif (interferon beta-1a) (PG231, Ver. 2)
- Rebyota (fecal microbiota, live - jslm) (PG240)
- Recorlev (levoketoconazole) (PG115, Ver. 4)
- Restasis (cyclosporine ophthalmic emulsion 0.05%) (PG025)
- Rexulti (brexipiprazole) (PG074)
- Rezdiffra (resmetirom) (PG198, Ver. 2)
- Rezzayo (rezafungin) (PG145)
- Rivastigmine (Exelon) (PG212)
- Rosuvastatin (Crestor) (PG006, Ver. 8)
- Sancuso (granisetron) Patch (PG007, Ver. 7)
- Sancuso (granisetron) Patch (PG007-REG, Ver. 7)
- Savella (milnacipran) (PG062)
- Sildenafil (PAH, Viagra) (PG051, Ver. 7)
- Sirturo (bedaquiline) (PG242, Ver. 2)
- Sodium oxybate (Xyrem) (PG009, Ver. 8)
- Sohonos (palovarotene) (PG183)
- Spevigo (spesolimab-sbzo) (CG071)
- Spravato (esketamine) (PG257, Ver. 1)
- Sunosi (solriamfetol) (PG097)
- Syfovre (pegcetacoplan injection) (PG150)
- Tadalafil (Adcirca, Alyq, Chewtadzy, Cialis, Tadliq) (PG052, Ver. 8)
- Tarpeyo (budesonide DR) (PG116, Ver. 4)
- Teriflunomide (Aubagio) (PG232, Ver. 2)
- Testosterone replacement therapy (PG122, Ver. 5)
- Tevimbra (tislelizumab) (PG210, Ver. 2)
- Tezspire (tezepelumab) (PG118, Ver. 5)
- Thyrogen (thyrotropin alfa) (PG140)
- Tremfya (guselkumab) (PG250)
- Tysabri (natalizumab) (PG195)
- Tzield (teplizumab-mzwv) (CG072)
- Urea Cycle Disorder (UCD) Treatment Agents (PG187)
- Varubi (rolapitant) (PG178)
- Vascepa (icosapent ethyl) (PG125)
- Velphoro (sucroferric oxyhydroxide) (PG179, Ver. 3)
- Vemlidy (tenofovir alafenamide) (PG010, Ver. 7)
- Veozah (fezolinetant) (PG215, Ver. 2)
- Verkazia (cyclosporine ophthalmic emulsion) 0.1% (PG236)
- Verquvo (vericiguat) (PG091)
- Vesicular Monoamine Transporter Type 2 (VMAT2) Inhibitors (PG144, Ver. 3)
- Vowst (fecal microbiota spores, live-brpk) (PG241)
- Vumerity (diroximel fumarate) (PG233, Ver. 2)
- Vyjuvek (beremagene geperpavec-svdt) (PG147, Ver. 3)
- Vyvanse (lisdexamfetamine) (PG098)
- Wakix (pitolisant hydrochloride) (PG247)
- Wegovy (semaglutide) for Cardiovascular Risk Reduction (PG194)
- Weight Loss Agents (PG070)
- Winrevair (sotatercept-csrk) (PG207, Ver. 2)
- Xarelto (rivaroxaban) 1mg/mL Granules for Suspension (PG137, Ver. 3)
- Xdemvy (lotilaner) (PG161, Ver. 3)
- Xifaxan (rifaximin) 550 mg Tablets (PG022, Ver. 8)
- Xiidra (lifitegrast) (PG197)
- Xywav (calcium, magnesium, potassium, and sodium oxybates) (PG248, Ver. 2)
- Ycanth (cantharidin) (PG162, Ver. 3)
- Zelsuvmi (berdazimer topical gel, 10.3%) (PG201, Ver. 2)
- Zepbound (tirzepatide) for the Treatment of Obstructive Sleep Apnea (PG255, Ver. 2)
- Zeposia (ozanimod) (PG234, Ver. 3)
- Zokinvy (lonafarnib) (PG092)
- Zolgensma (onasemnogene abeparvovec-xioi) (CG061)
- Zortress (everolimus) (PG033)
- Zurzuvae (zuranolone) (PG182)
- Zynteglo (betibeglogene autotemcel) (CG073)
Adopted Guidelines
- Caremark Prior Authorization Criteria